CA
NZ
UK
AU
IND
US
Galmed Pharmaceuticals (Nasdaq: GLMD) has faced significant challenges in recent times, particularly with the termination of its NASHDrug Development. The company's decision to acquire Colospan Ltd, a medical device company, has been met with skepticism by investors, leading to a 33% decline in its …
Blockbuster Phase 1/2 Data Drives the Session
Major Analyst Upgrades Across the BoardTruist raised its price target to $440, JPMorgan raised its target to $466, and Mizuho raised its target to $460 — all maintaining Buy or Outperform ratings — reflecting growing institutional conviction in UNH's recovery trajectory.
55% Revenue Growth in Q1 2026Lilly reported Q1 2026 revenue of $19.8 billion — up 55.5% year-on-year — with EPS of $8.55 significantly ahead of the $6.79 consensus, while raising its full-year revenue outlook to $85 billion.
Conference Reaffirmation Anchors the Session
Selloff Context: Macro Pressure Without Company Catalyst
Ensign Shares Slide as Legal Risk Hits Sentiment
The recent collaboration between Nurix Therapeutics and Roche marks a significant turning point in the landscape of oncology drug discovery. Traditional small molecule inhibitors often encounter resistance mechanisms in cancer treatment, particularly in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia. …
Shattuck Labs (Nasdaq: STTK) has unveiled promising Phase 1 results for its Crohn's disease drug SL-325, a monoclonal antibody targeting the DR3 receptor to block TL1A-induced inflammation. The reported immunogenicity rate of 3.7% is a critical differentiator in a therapeutic landscape where conventional biologics …
In the ongoing battle against infectious diseases, the need for effective vaccines that can be deployed rapidly in outbreak zones has never been more pressing. Soligenix, a biopharmaceutical company focused on developing treatments for rare diseases and biodefense, is stepping into this critical arena …
Please wait processing your request...